Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | STK3 | Q13188 | 1/20 | 0.46 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2195949 | 0.86 | PIK3CA (0.61) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL561900 | 0.85 | PIK3CA (0.58) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL560807 | 0.83 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL561550 | 0.77 | PIK3CA (0.75) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL2189861 | 0.76 | PIK3CA (0.74) | PIK3CAROCK1ROCK2AURKAERBB2 | |
| SCHEMBL560911 | 0.76 | PIK3CA (0.59) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL561177 | 0.74 | PIK3CA (0.53) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL560813 | 0.73 | PIK3CA (0.70) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL560837 | 0.73 | PIK3CA (0.71) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL561019 | 0.72 | PIK3CA (0.68) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | claimed |
| EP-2356117-B1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-09-26 | — | — | EP | claimed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | claimed |
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2356117-B1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2356117-B1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
| EP-2356117-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010059788-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059788-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | PIK3CA 1/4885PIK3CD 2/4885PIK3CB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.